A little over a month after announcing her departure from Moderna, Kate Cronin has begun her “next adventure.” Cronin has ...

MRNA reports mixed Q1 results. The company reiterates 2025 sales guidance but announces a cost-cutting initiative to reduce ...

Moderna faces revenue declines, regulatory setbacks, and market challenges as COVID-19 vaccine demand wanes. Learn more about ...

Reports first quarter revenues of $0.1 billion, GAAP net loss of $(1.0) billion and GAAP EPS of $(2.52) Reiterates 2025 ...

Moderna (MRNA) was in focus Thursday morning after the vaccine maker announced plans to expand its cost efficiency and ...

Moderna (Nasdaq: MRNA) today reported financial results and provided business updates for the first quarter of 2025, which ...

Q1 2025 Earnings Call Transcript May 1, 2025 Moderna, Inc. beats earnings expectations. Reported EPS is $-2.52, expectations were $-2.92. Operator: Good day, and thank you for standing by. Welcome to ...

Have you ever wondered about what became of COVID vaccine companies after the pandemic settled down? Find out in this article ...

With license in hand and the plant now fully operational, Moderna is free to use the site for commercial production of mRNA shots, which will then be beholden to MHRA's standard review process ...

Moderna Q1 EPS loss of $(2.52 ... period last year and the continued normalization of COVID-19 into a seasonal commercial market, with demand expected to be concentrated in the second half ...

With several Phase 3 readouts approaching and continued momentum toward 10 product approvals, we remain confident in Moderna's long-term outlook." Recent progress includes: Commercial Updates ...

Moderna's RSV vaccine for adults aged 60 years ... last year and the continued normalization of COVID into a seasonal commercial market, with demand expected to be concentrated in the second ...